Alnylam Pharmaceuticals, Inc. vs Johnson & Johnson — Stock Comparison
Alnylam Pharmaceuticals, Inc. (ALNY) and Johnson & Johnson (JNJ) are both listed on US exchanges. This page compares their Q·Score ratings, key fundamentals (P/E, margins, growth), and Wall Street analyst consensus side by side. Data sourced from Yahoo Finance and updated on each page load.
Alnylam Pharmaceuticals, Inc. narrowly edges Johnson & Johnson on Q·Score (7.8 vs 7.1 out of 10), led by Growth (8 vs 5.1) and Valuation (9.1 vs 7.3). Johnson & Johnson scores higher on Quality, reflecting stronger profitability and returns. Analyst consensus targets imply greater upside for ALNY (+56.9%) than for JNJ (+10.7%).
Price Performance
Normalised to 100 at period start — shows relative performance.
Q·Score Breakdown
Consensus analyst target of $436.32 is 57% above current price.
High-quality business with 26% return on equity and 22% profit margins.
⚠ earnings contracting 53% year-over-year.
Analyst Consensus
Fundamentals
Frequently Asked Questions
ALNY vs JNJ: which stock scores better overall?
Based on Q·Score, Alnylam Pharmaceuticals, Inc. (ALNY) scores 7.8/10 versus Johnson & Johnson (JNJ) at 7.1/10. The Q·Score measures five dimensions: Quality, Health, Growth, Valuation, and Sentiment. For informational purposes only — not financial advice.
Which has better revenue growth: ALNY or JNJ?
Alnylam Pharmaceuticals, Inc. (ALNY) scores higher on Growth (8/10 vs 5.1/10). Alnylam Pharmaceuticals, Inc. reports revenue growth (96.4% YoY) while Johnson & Johnson reports (9.9% YoY). Growth scores reflect revenue and earnings momentum relative to sector peers.
Is ALNY or JNJ more attractively valued?
Alnylam Pharmaceuticals, Inc. (ALNY) scores higher on Valuation (9.1/10 vs 7.3/10). ALNY trades at 20.2× P/E versus JNJ at 18.0×. Valuation is assessed using P/E ratio, analyst price targets, and 52-week range positioning relative to sector peers.
What do analysts say about ALNY vs JNJ?
There are 25 analysts covering ALNY with a consensus price target of $436.32, and 23 analysts covering JNJ with a consensus target of $252.87. Analyst consensus ratings are aggregated from Wall Street research and do not constitute investment advice.
Which is more profitable: ALNY or JNJ?
Johnson & Johnson (JNJ) scores higher on Quality (9.3/10 vs 8.2/10). Net profit margin: ALNY at 12.6%, JNJ at 21.8%. Quality scores reflect profit margins, return on equity, and free cash flow generation.
Which has stronger financial health: ALNY or JNJ?
Johnson & Johnson (JNJ) scores higher on Financial Health (6.5/10 vs 6.2/10). Market beta: ALNY at 0.27, JNJ at 0.26. Health scores consider beta, debt-to-equity, and current ratio. All investments carry risk — this is not investment advice.
What are the market caps of ALNY and JNJ?
Alnylam Pharmaceuticals, Inc. (ALNY) has a market capitalisation of $37.1B, while Johnson & Johnson (JNJ) has a market cap of $549.8B. Market cap data is sourced from Yahoo Finance and reflects the most recent available figures.
Related Comparisons
Q·Score is an educational tool and is not financial advice. Data provided by Yahoo Finance. Updated on each page load. How it's calculated →